We track quarterly 13F filings from hedge funds and other notable investors for a variety of purposes. For one, we can use the information to develop investing strategies; for example, our research has indicated that the most popular small cap stocks among hedge funds generate an average excess return of 18 percentage points per year (learn more about our small cap strategy). We can also see individual managers’ picks in a number of areas, including each one’s favorite small cap stocks (which we define as those with market caps between $1 billion and $5 billion). Blindly imitating these picks isn’t wise, but investors can think of this process as similar to a stock screen in outputting interesting names for further research. Read on for our quick take on the five largest small cap holdings in Larry Robbins’ Glenview Capital’s portfolio as of the end of December (or see the full list of the fund’s stock picks):
Glenview reported a position of a little less than 14 million shares in Tenet Healthcare Corp (NYSE:THC), a $4.9 billion market cap operator of hospitals and outpatient health care centers. While Tenet Healthcare Corp (NYSE:THC)’s adjusted earnings numbers have missed expectations the past couple quarters, Wall Street analysts expect the bottom line to improve over the next couple years with the result being a forward P/E of 11. Hospitals are trading at low multiples in general, however, and it might be wise to at least start with looking at Tenet Healthcare Corp (NYSE:THC)’s peers. Blue Ridge Capital, managed by Tiger Cub John Griffin, owned 1.7 million shares according to that fund’s own 13F (find Griffin’s favorite stocks).
Flextronics International Ltd. (NASDAQ:FLEX), a provider of design and engineering services to manufacturing companies which has a market capitalization of $4.4 billion, was another of Glenview’s small cap picks. While the stock is cheap in terms of its earnings multiples- for example, the trailing P/E is only 11- business has been poor recently. In its most recent quarter sales fell 18% compared to the same period in the previous fiscal year, driving earnings down substantially. As a result we would avoid the stock.